Novartis Acquires Avidity Biosciences in $12 Billion Deal, Bolstering RNA Pipeline
Novartis agrees to acquire Avidity Biosciences for $12 billion to secure its Antibody Oligonucleotide Conjugate (AOC) platform. Learn what this means for genetic medicine and Novartis’s pipeline.